SVEP1 is a recently identified multidomain cell adhesion protein, homologous to the mouse polydom protein, which has been shown to mediate cell-cell adhesion in an integrin-dependent manner in osteogenic cells. In this study, we characterized SVEP1 function in the epidermis. SVEP1 was found by qRT-PCR to be ubiquitously expressed in human tissues, including the skin. Confocal microscopy revealed that SVEP1 is normally mostly expressed in the cytoplasm of basal and suprabasal epidermal cells.
| INTRODUCTION
Adhesion molecules play a critical role within the epidermis, responsible for epidermal-dermal junction integrity as well as epidermal barrier function. [1, 2] Consequently, abnormal function of these proteins is associated with numerous and mostly severe congenital disorders including various forms of epidermolysis bullosa and disorders of cornification. [3] The SVEP1 gene is located on 9q32, spans 214 kb of genomic DNA and consists of 48 exons, encoding a secreted multidomain protein which harbours sushi (named also complement control protein; CCP), von Willebrand factor (VWF) type A, epidermal growth factor (EGF) and pentraxin-domain motifs. In addition, it contains additional domains including TNF-receptor cysteine-rich domains, hyaline repeat domains that are involved in cell adhesion, a RGD cell attachment site and a ADAM disintegrin and metalloproteinase cysteine-rich (ACR)
domain that plays a role in cell tumorigenesis. [4] [5] [6] SVEP1 displays more than 80% homology to the mouse polydom protein. [5, 7, 8] Recently, it has been shown that SVEP1 is an integrin α9β1 ligand with an affinity that far exceeds that of other known integrin α9β1 ligands, and as such, it was found to mediate cell-cell adhesion in an integrin-dependent manner in mesenchymal cells. Consistent with these findings, SVEP1
was found to co-localize with integrin α9β1 in mouse tissues in vivo. [8] The presence of a CCP domain with a selectin superfamily signature associated with an EGF domain is reminiscent of the structure of selectins which mediate dynamic cell-cell interactions in several tissues. Accordingly, anti-SVEP1 antibodies were found to perturb cell adhesion in murine bone marrow-derived osteoblastic cells. [5] SVEP1 has been shown to be expressed in murine placenta, lungs, intestine, stomach, skeletal tissue and preosteoblastic cells; human, murine and rat bone marrow-derived mesenchymal stem cells; and human placenta, endothelial cells and breast cancer cell lines, while its expression has been shown to be regulated by oestrogen and tumor necrosis factor (TNF)-α. [4] [5] [6] [7] [8] [9] [10] [11] [12] In contrast, the pattern of expression of SVEP1 and its role in human skin remain to be determined. Given the contribution of SVEP1 to the maintenance of cell-cell adhesion in many tissues, and the importance of adhesion molecules for skin function, we characterized SVEP1 expression and function in the epidermis.
| METHODS

| Primary cell cultures
Primary keratinocytes (KCs) and fibroblasts were isolated from adult skin obtained from plastic surgery specimens after having received written informed consent from the donors according to a protocol reviewed and approved by our institutional review board as previously described. [13] [14] [15] KCs were maintained in KC growth medium (KGM) (Lonza, Walkersville, MD, USA). Fibroblasts were cultured in Dulbecco's modified essential Medium (DMEM) supplemented with 20% foetal calf serum (FCS) (both were purchased from Biological Industries, Beit Haemek, Israel).
| siRNA transfection
Primary KCs and fibroblasts were cultured in 100-mm culture plates at 37°C in 5% CO 2 in a humidified incubator and were harvested at 60% confluence. To downregulate SVEP1 expression, we used human SVEP1 small interference RNAs (siRNA) from GE Healthcare Dharmacon (Lafayette, CO, USA), with the following sequences: 5′-GCUACUAUCUAUUGGGUGA-3′;
5′-AGUCUAUAUCGAUGGGAAA-3′; 5′-GGGCAGUGGAGUAGUCC UA-3′; 5′-GUGGAAAGAACGUCGAUGA-3′. As control siRNA, we used Stealth™ RNAi Negative Control Duplex (Invitrogen, Carlsbad, CA, USA). One hundred and eighty pmol of siRNAs was transfected into primary KCs and fibroblasts using Lipofectamine RNAiMax (Invitrogen). The transfection medium was replaced after 6 hours with KGM (for KCs) or DMEM (for fibroblasts). Seventy-two hours following transfection, the transfected cells were trypsinized and used for organotypic cell cultures as described below.
| Organotypic cell cultures
Seventy-two hours after transfection, control and SVEP1
knocked-down human fibroblasts were trypsinized, counted and re-suspended in DMEM medium containing 20% FCS (Biological Industries) as previously described. [13, 14] Thereafter, 0.1×10 6 fibroblasts per mL of type I bovine collagen matrix (Advanced BioMatrix, San Diego, CA, USA) were mixed, and 2.5 mL of this solution was poured into 3-μm filter tissue culture inserts (BD, Franklin Lakes, NJ, USA) and allowed to gel for 2 hours at 37°C in a humidified atmosphere according to a protocol modified from Mildner et al. [16] The gels were then equilibrated with KGM (Lonza) for 2 hours, and 1.0×10 6 control or SVEP1 knocked-down human KCs per cm 2 growth area were seeded onto the matrix at a total volume of 2 mL medium per insert. After 24 hours, the system was raised to airliquid interface and medium was replaced by KC culture medium (KCM) as previously described. [17] Models were grown for 10 days, and medium was changed every other day. For each set of experiments (total of two experiments performed under identical conditions), KCs and fibroblasts were derived from the same donor and used at the third passage. Punch biopsies were obtained from organotypic cell cultures and fixed in 4% paraformaldehyde. Fivemicrometer-thick paraffin-embedded sections were processed for haematoxylin-eosin staining or immunostaining. RNA was extracted from punch biopsies using RNeasy Fibrous Tissue Mini Kit (Qiagen, Hilden, Germany).
| Quantitative RT-PCR
For quantitative real-time PCR, cDNA was synthesized from 1000 ng of total RNA using qScript kit (Quanta Biosciences, Gaithersburg, MD, USA 
| SVEP1 knockout mice
This strain was generated by the Knockout Mouse Phenotyping
Program (KOMP) at the Jackson Laboratory using embryonic stem (ES) cells provided by the International Knockout Mouse Consortium.
A knockout-first beta-galactosidase reporter cassette [18] We generated embryos from timed pregnant females and necropsied entire litters at embryonic day 18.5. Embryos were harvested and assessed at embryonic day 18.5 (E18.5) and fixed for 3 days in 4%
paraformaldehyde. Skin from the trunk was removed and processed for histology.
| SVEP1 knockdown in zebrafish and morphant analysis
Adult wild-type zebrafish were maintained under standard conditions at 28.5°C. Zebrafish embryos and larvae were also maintained at 28.5°C in embryo medium. [19] All animals were housed in the Embryos at the one-to two-cell stage were injected with the morpholinos using glass microelectrodes fitted to a gas pressure injector (PL1-100; Harvard Apparatus, Holliston, MA, USA). Electrodes were pulled (P-97, Flaming/Brown; Sutter Instrument, Novato, CA, USA) and filled with morpholino and phenol red (final concentration 0.025%) to visualize the injected embryos. Control and morphant larvae at 3 days postfertilization (dpf) were processed for scanning or electron microscopy as previously described. [19] Specimens were imaged in a JEOL-T330A scanning electron microscope (JEOL, Tokyo, Japan) at 15 kV or a JEOL JEM-1010 transmission electron microscope fitted with a Hamamatsu digital camera (Hamamatsu Photonics, Hamamatsu City, Japan) and AMT
Advantage image capture software (AMT, Danvers, MA, USA).
| Immunohistochemistry
For SVEP1 immunofluorescence analysis of skin biopsies, 5-μm paraffin-embedded sections were baked overnight at 37°C and deparaffinized using xylene/ethanol. Antigen retrieval was accomplished Negative control was obtained by omitting the primary antibody. As a positive control, we used a normal placenta tissue, [5] which stained positively with the antibody (Fig. S1 ). Samples were examined using either a Nikon 50I microscope connected to DS-RI1 digital camera (Nikon, Brighton, MI, USA) or a Zeiss LSM700 confocal microscope (Carl Zeiss, Oberkochen, Germany) for fluorescence image acquisition.
Immunostaining with mouse anti-human Ki-67 antibody (DAKO, Hamburg, Germany) was performed as previously described.
[20]
| Immunostaining of KCs and fibroblasts
Keratinocytes and fibroblasts that were harvested from punch biopsies were grown on glass coverslips and fixed with 4% paraformalde- 
| Cell-cycle analysis
For cell-cycle analysis, primary KCs were seeded in 6-well plates USA) instrument, and data were analysed using FACSDiva (v 6.1.3) to determine the relative amounts of cell-cycle phases.
| Dispase assay
Electroporation of human foreskin KCs was performed using 50 nm siRNA targeting desmoplakin (DP) (Life Technologies, Grand
Island, NY, USA), SVEP1 (Dharmacon) or a scrambled control siRNA (Dharmacon). DP was used as a positive control for decreased intercellular adhesion. Seventy-two hours following siRNA transfection, cell monolayers were seeded in triplicate into 6-well plates. Twentyfour hours after reaching confluency, cultures were washed twice in Dulbecco's PBS (DPBS) and then incubated in 2 mL of dispase (2.4 U/ mL; Roche Diagnostics GmbH, Indianapolis, IN, USA) for 30 minutes. [21, 22] Released monolayers were subjected to mechanical stress to induce fragmentation. Fragments were counted using a dissecting microscope (MZ6; Leica, Buffalo Grove, IL, USA).
| RESULTS
| SVEP1 is ubiquitously expressed in normal human tissues
As SVEP1 normal expression was previously investigated mostly in cell lines and murine tissues, [4] [5] [6] [9] [10] [11] we initially assessed its normal expression in human tissues. Using qRT-PCR, we observed ubiquitous expression of SVEP1 in a wide array of normal human tissues, with maximal expression in the placenta ( Figure 1A ). Of note, strong expression was also demonstrated in human epidermal KCs and skin fibroblasts ( Figure 1B ). This is in line with previous studies in mice demonstrating ubiquitous expression of the full-length polydom gene transcript in different tissues. [4] We then established the protein expression pattern of SVEP1 in human skin. Immunostaining showed that although SVEP1 immunoreactivity was seen throughout the human epidermis, it is most prominently expressed in the basal and lower suprabasal layers of the epidermis. In addition, prominent expression of SVEP1 was shown in dermal fibroblasts residing in the upper dermis ( Figure 1C,D) .
In primary epidermal KCs and fibroblast cell cultures from healthy individuals, SVEP1 expression was most prominent in the nuclear and peripheral cytoplasmic compartments of the cells ( Figure 1E ,F and Fig.   S2 ). This contrasts with previous reports that demonstrated cell membrane and cytoplasmic immunoreactivity in other cell lines.
[5]
| SVEP1 silencing in primary KCs is associated with abnormal expression of differentiationassociated genes
To examine the possibility that SVEP1 expression in the skin may reflect a role for this protein during epidermal ontogenesis, we knocked down primary human KCs for SVEP1 and assessed the effect of decreased SVEP1 expression on various epidermal differentiation-associated genes.
SVEP1-silenced KCs showed downregulation of the differentiationassociated keratins (KRT1 and KRT10) [23] and upregulation of TGM1 encoding transglutaminase 1, while there was no significant difference in the expression of the proliferation-associated keratin genes KRT5, KRT14 and KRT6a, [23] at the mRNA level (Figure 2A ).
| Human skin equivalents silenced for SVEP1 show acanthosis and abnormal expression of differentiation markers
Because SVEP1 downregulation in keratinocyte cell cultures seemed to result in abnormal regulation of differentiation-associated genes, F I G U R E 1 SVEP1 expression in human tissues. (A) SVEP1 mRNA expression was evaluated using qRT-PCR in normal human tissues.
Results are expressed as relative to gene expression in the placenta normalized to ACTB RNA levels; (B) SVEP1 mRNA expression in cultured human keratinocytes (KCs) and fibroblasts. Results are expressed as % of expression relative to keratinocytes and are normalized to ACTB RNA levels; (C) SVEP1 immunostaining of skin biopsies obtained from healthy individual reveals SVEP1 expression in all epidermal layers and in dermal fibroblasts residing in the upper dermis; (D) a higher magnification demonstrates increased expression of SVEP1 in the basal and suprabasal layers of the epidermis (bars; c=100 μm, d=40 μm). Dotted lines represent epidermal-dermal junction and localization of the basement membrane; E, epidermis; D, dermis; SC, stratum corneum; SG, stratum granulosum; BL, basal layer; (E, F) KCs (E) and fibroblasts (F) isolated from skin biopsies obtained from healthy individuals demonstrate SVEP1 expression most prominent in the peripheral cytoplasmic and nuclear compartments of the cells (bar=40 μm)
we hypothesized that it may be involved in epidermal differentiation.
To assess this possibility, we established a SVEP1-silenced organotypic three-dimensional skin model (Fig. S3) . SVEP1-silenced organotypic skin model displayed a significantly thicker epidermis (acanthosis), with no evidence of abnormal cell-cell adhesion, compared to control skin models ( Figure 2B-D) . In line with these results, there was no significant difference in the expression of several adhesion markers between SVEP1-silenced and control organotypic skin models (Fig.   S4 ). In addition, SVEP1 silencing resulted in abnormal RNA expression of differentiation-associated markers compared to control skin models ( Figure 2E ). In contrast to the findings in SVEP1-silenced primary KCs, SVEP1-silenced skin equivalents revealed slight but significant reduction in the expression of the KRT5 and KRT6a as well, while the expression of KRT14 was not significantly affected ( Figure 2E ). Given the fact that skin models were grown for 10 days prior to obtaining skin biopsies, no evidence of proliferative cells was documented by
Ki67 staining in both control and SVEP1-deficient skin models (data not shown). We therefore used cell-cycle FACS analysis to ascertain the effect of SVEP1 downregulation on KCs proliferation. We found that KCs downregulated for SVEP1 do not demonstrate significant changes in proliferation indices compared to control siRNA-treated keratinocytes (Fig. S5 ).
| Svep1 knockdown in a zebrafish model reveals abnormal epidermal morphology and disadhesion of epidermal cells
To assess the importance of SVEP1 for normal skin homoeostasis in vivo, we studied a Svep1-null mouse model generated through the KOMP 2 at the Jackson Laboratory (Svep1 tm1b(EUCOMM)Hmgu /J). Svep1-null mice were found to be embryonic lethal, with no homozygous null animal identified at wean (n=98). Svep1-null embryos were obtained via heterozygous crosses at E18.5. Mutant embryos showed gross morphological abnormalities including oedema, abnormal skin coloration and tail/limb abnormalities. In line with the results in organotypic skin models, skin biopsies of these embryos revealed significantly thicker epidermal layer compared to heterozygous controls (Fig. S6 ).
Because we could not study adult Svep1-null mice, we downregulated Svep1 in zebrafish embryos with a Svep1-specific splice morpholino ( Figure 3A) . RT-PCR of total RNA extracted from zebrafish 3 days after morpholino injection revealed that essentially all (>90%) of the Svep1 pre-mRNA remained unprocessed, attesting to the efficiency of the morpholino knockdown ( Figure 3B ). Injection of standard control morpholino (scMO) did not affect Svep1 pre-mRNA splicing ( Figure 3B ). Scanning electron microscopy showed that the morphant larvae injected with a splice morpholino for Svep1 gene display rugged morphology of the epidermis with perturbed microridge formation in the centre of the KCs. This was in contrast to the standard control morpholino-injected control larvae that demonstrated well-demarcated KCs with normal microridges at the cell-cell borders ( Figure 3C,D) . Transmission electron microscopy analysis demonstrated abnormal epidermal cell-cell adhesion with disadhesion between cells (but normal-appearing desmosomes) in Svep1 morphant larvae compared to control ( Figure 3E ).
| SVEP1-deficient human epidermal monolayers reveal normal cell-cell adhesion
Given the abnormal epidermal cell adhesion observed in Svep1-deficient morphant larvae, we aimed at determining the role of SVEP1 in cell-cell adhesion in human KCs. We therefore conducted Results were normalized to GAPDH RNA levels; (B-E) human primary KCs and fibroblasts transfected with SVEP1 siRNA or control siRNA were used to generate skin equivalents. The experiment was repeated twice under identical conditions (the results of the first experiment are designated as "1st model," while the results of the second experiment are designated as "2nd model"). Punch biopsies were obtained from skin equivalents at day 10 and stained for haematoxylin and eosin (H&E; bar=50 μm). Epidermal thickness was evaluated in SVEP1-deficient and control siRNA-treated skin equivalents, in both experiments (B). Note significant acanthosis in skin equivalents downregulated for SVEP1 (D) compared to control (C). Dotted lines represent epidermal-dermal junction. E, epidermis; D, dermis; SC, stratum corneum; (E) RNA was extracted from punch biopsies derived from skin equivalents, and gene expression was assessed using qRT-PCR. Results are expressed as gene expression in downregulated skin equivalents relative to control skin equivalents. Data were normalized to GAPDH RNA levels (t test; *P<.05, **P<.01, ***P<0.001)
a dissociation assay in epidermal monolayers generated from SVEP1-specific siRNA-and control siRNA-transfected KCs (Fig. S7) . We observed that the loss of SVEP1 did not result in an adhesion defect in keratinocytes as determined by a dispase assay (Figure 4 ). While we cannot rule out that a more complete SVEP1 knockdown would have a detrimental impact on adhesion, the level of adhesion in KCs was significantly reduced upon knockdown of the obligate desmosome component, desmoplakin (Figure 4 ).
| DISCUSSION
Here, we provide the first evidence that SVEP1, a recently identified integrin α9β1 ligand, is expressed in normal human skin and plays a hitherto unknown role during epidermal differentiation.
SVEP1 expression was previously investigated mostly in cell lines
and murine tissues while here, we provide the first evidence that SVEP1 is normally expressed in a wide array of human tissues with relatively high level of expression in human skin. Recently, several studies demonstrated the significant role played by SVEP1 in systemic conditions. A missense variant in the SVEP1 gene was associated with an increased risk of coronary artery disease in association with type 2 diabetes and higher systolic and diastolic blood pressure. [24] Moreover, a polymorphism in the SVEP1 gene was associated with altered 28-days mortality of septic shock, and SVEP1 knockdown in a cellular model of sepsis influenced several inflammatory processes. [25] In line with these findings, SVEP1 gene expression was increased in an vitro cell culture model of endotoxemia. [12] Integrin α9β1 is known to bind a panel of extracellular matrix
proteins, including tenascin-C, osteopontin, fibronectin isoform containing an EIIIA domain, membrane proteins (ADAM proteases and VCAM-1) and growth factors (VEGF and NGF). [26] [27] [28] [29] [30] [31] [32] Polydom was shown to bind integrin α9β1 ligand in vivo with higher affinity than that of known ligands including tenascin-C. [8] Here, we show that SVEP1 deficiency affects epidermal differentiation. Of interest,
another integrin α9β1 ligand, EMILIN1, [33] was shown to affect epidermal cell proliferation, possibly through direct binding to integrin α9β1
(known to be expressed on basal KCs) and activation of the Erk1/2
and Akt/PI3K pathways. [33] Of interest, although SVEP1 was shown to be present throughout the entire epidermis, it was more prominently expressed in the basal and lower suprabasal layers of the epidermis as well as in upper dermal fibroblasts. This observation is reminiscent of the pattern of expression of integrin α9β1 which SVEP1 binds. Integrin α9β1 has been shown to mediate activation of the ERK signalling pathway, [34, 35] while attenuation of the latter has been shown to promote epidermal differentiation. [36, 37] Collectively, these data suggest that the effect of SVEP1 on epidermal differentiation may involve SVEP1
binding to integrin α9β1.
Regardless of its exact mechanism of action, SVEP1 expression was found to be required for the normal expression of differentiationassociated genes. Its absence in both in vitro (human tridimensional cultures) and in vivo (mice and zebrafish knockdown experiments) models resulted in perturbed epidermal differentiation. SVEP1
has been shown to regulate cell-cell adhesion in human bone tissues, [8] and SVEP1 knockdown in a cellular model of sepsis altered the expression of mediators of leucocyte adhesion to the vascular endothelium. [25] Consistent with this observation, blisters were observed in SVEP1 knocked-down zebrafish larvae. However, no evidence for abnormal intercellular adhesion was observed in human skin equivalents, mice model or in KC monolayers, while both SVEP1-deficient organotypic skin models and Svep1-null mice revealed significant acanthosis compared to controls. The fact that SVEP1 seems to affect epidermal differentiation in all models but is apparently not required for normal cell-cell adhesion in mammalian systems suggests that these two functions are not related. Alternatively, we cannot rule out that perturbation of cell-cell adhesion is dependent on the degree of SVEP1 downregulation which may vary from one model to the other.
Taken together, our study identifies for the first time a role for SVEP1 in the regulation of epidermal differentiation. Whether its activity is mediated by binding to integrin α9β1 or another receptor remains to be determined.
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